Omicral (Itraconazole)

Omicral (itraconazole) is an azole antifungal that acts on invasive fungal disease pathways.

• Aspergillosis: Reduces fungal burden and improves survival in invasive pulmonary aspergillosis.
• Candidiasis: Treats systemic candidemia and deep‑tissue candidiasis.
• Histoplasmosis: Controls infection in disseminated histoplasmosis.
• Blastomycosis: Clears fungal lesions in blastomycosis.
• Sporotrichosis: Improves outcomes for cutaneous and disseminated sporotrichosis.

• Itraconazole inhibits the fungal cytochrome P450 enzyme lanosterol 14α‑demethylase, blocking the conversion of lanosterol to ergosterol. This disruption of ergosterol synthesis compromises the fungal cell membrane, increasing permeability and leading to cell death or growth arrest.

Adverse reactions to itraconazole vary in frequency and severity.

Common Side Effects

• Nausea: Mild to moderate stomach upset.
• Headache: Transient headache reported by some patients.
• Diarrhea: Loose stools occurring during therapy.
• Abdominal pain: Cramping or discomfort in the abdomen.
• Rash: Mild skin erythema or itching.
• Elevated liver enzymes: Mild, reversible increases in hepatic transaminases.

Serious or Rare Side Effects

• Hepatotoxicity: Clinically significant liver injury, potentially leading to jaundice.
• Congestive heart failure: Worsening of pre‑existing cardiac failure.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Visual disturbances: Blurred vision or photophobia.
• QT prolongation: Cardiac rhythm changes detectable on ECG.
• Anaphylaxis: Immediate hypersensitivity reaction requiring emergency care.

When prescribing itraconazole, clinicians should consider several safety measures.

• Liver function monitoring: Check baseline enzymes and repeat during therapy.
• Cardiac assessment: Evaluate for history of heart failure before use.
• Drug‑interaction review: Identify concomitant medications that affect CYP3A4.
• Pregnancy and lactation: Avoid use unless benefits outweigh risks.
• Renal impairment: Adjust monitoring in patients with severe kidney disease.
• Store at ambient temperature: Keep below 25 °C, in original packaging, protected from moisture.

Itraconazole interacts with many medicines through CYP3A4 inhibition and other pathways.

Major Interactions (Avoid)

• Simvastatin: Increased risk of rhabdomyolysis.
• Midazolam: Potentiated sedation and respiratory depression.
• Quinidine: Elevated quinidine levels leading to arrhythmias.
• Ritonavir: Marked increase in itraconazole exposure.
• Cisapride: Risk of serious cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

• Warfarin: Enhanced anticoagulant effect, monitor INR.
• Phenytoin: Reduced itraconazole levels, may require dose adjustment.
• Ketoconazole: Additive hepatotoxic potential.
• Digoxin: Slight increase in serum digoxin concentrations.
• Rifampicin: Decreased itraconazole efficacy due to enzyme induction.